| Literature DB >> 32303686 |
Zhihao Liu1, Ying Yang1, Yan Zhang1, Liling Xie2, Qinqin Li2, Yun Song3,4, Lishun Liu3, Chengzhang Liu5, Benjamin Xu6, Binyan Wang4,5, Tieci Yi1, Fangfang Fan1, Wei Ma1, Haoyu Weng1, Nan Zhang1, Xiping Xu2,3, Xiaobin Wang7, Xianhui Qin2,4, Yong Huo1, Jianping Li8,9.
Abstract
We aimed to investigate the association of brachial-ankle pulse wave velocity (baPWV) with carotid plaque presence and carotid plaque number in a Chinese hypertensive population. A total of 13,554 hypertensive subjects from the China Stroke Primary Prevention Trial (CSPPT) were recruited. Arterial stiffness and carotid plaque were evaluated by baPWV and B-mode ultrasonography, respectively. Multivariate logistic regression analysis was used to determine the correlation of baPWV and carotid plaque presence. Multinomial logistic regression analysis was used to determine the correlation of baPWV and carotid plaque number. Further interactions between baPWV and carotid plaque presence were examined using subgroup analysis. Continuous baPWV was positively correlated with carotid plaque presence (OR = 1.05, 95% CI: 1.04-1.07) and carotid plaque number (one- to two-plaque group: OR = 1.04, 95% CI: 1.02-1.06; three-or-more-plaque group: OR = 1.09, 95% CI: 1.07-1.12). When baPWV was classified into quartiles, with the lowest quartile as reference, the ORs for having one, two, or three or more plaques increased in parallel with the quartiles of baPWV, indicating a dose-dependent effect. In a subgroup analysis, the association of baPWV and carotid plaque presence was more pronounced among younger participants (OR: 1.14 vs. 1.06 and 1.03 for the age groups <60 years, 60 ≤ 70 years, and ≥70 years, respectively, P for interaction <0.001). In a Chinese hypertensive population, baPWV was positively associated with carotid plaque presence and carotid plaque number. A more pronounced positive association between baPWV and carotid plaque presence was observed in younger participants.Entities:
Keywords: Age; Brachial–ankle pulse wave velocity; Carotid plaque number; Carotid plaque presence; Hypertension
Year: 2020 PMID: 32303686 PMCID: PMC7363666 DOI: 10.1038/s41440-020-0432-2
Source DB: PubMed Journal: Hypertens Res ISSN: 0916-9636 Impact factor: 3.872
Fig. 1Flowchart of the study
Characteristics of study subjectsa
| Total ( | Gender | |||
|---|---|---|---|---|
| Male ( | Female ( | |||
| Age, year | 64.3 (7.4) | 65.5 (7.4) | 63.6 (7.3) | <0.001 |
| Body mass index, kg/m2 | 24.9 (3.8) | 24.1 (3.5) | 25.5 (3.8) | <0.001 |
| baPWV, m/s | 17.2 (3.4) | 17.2 (3.4) | 17.3 (3.4) | 0.006 |
| Plaque presence, | <0.001 | |||
| No | 7893 (58.2) | 2692 (49.1) | 5201 (64.4) | |
| Yes | 5661 (41.8) | 2786 (50.9) | 2875 (35.6) | |
| Plaque number, | <0.001 | |||
| 1 | 2575 (19.0) | 1112 (20.3) | 1463 (18.1) | |
| 2 | 1467 (10.8) | 702 (12.8) | 765 (9.5) | |
| ≥3 | 1619 (11.9) | 972 (17.7) | 647 (8.0) | |
| SBP, mmHg | 135.4 (17.4) | 132.8 (16.9) | 137.2 (17.5) | <0.001 |
| DBP, mmHg | 82.0 (10.9) | 82.3 (11.3) | 81.8 (10.6) | 0.007 |
| Current smoking, | 2892 (21.4) | 2690 (49.2) | 202 (2.5) | <0.001 |
| Current drinking, | 3032 (23.2) | 2667 (52.7) | 365 (4.6) | <0.001 |
| Laboratory results, mmol/l | ||||
| Total cholesterol | 5.3 (1.1) | 5.1 (1.0) | 5.5 (1.1) | <0.001 |
| Triglycerides | 1.8 (1.4) | 1.5 (1.4) | 1.9 (1.5) | <0.001 |
| HDL cholesterol | 1.3 (0.3) | 1.3 (0.3) | 1.3 (0.3) | 0.096 |
| Fasting glucose | 6.2 (2.0) | 6.2 (2.0) | 6.3 (2.0) | 0.398 |
| Folate, ng/ml | 18.9 (15.4) | 18.4 (16.0) | 19.3 (15.0) | <0.001 |
| Serum homocysteine, μmol/l | 13.5 (7.2) | 15.3 (9.1) | 12.3 (5.2) | <0.001 |
| eGFR, mL/(min·1.73 m2) | 88.6 (14.9) | 87.1 (15.3) | 89.7 (14.5) | <0.001 |
| Medication use, | ||||
| Antihypertensive drugs | 13,148 (97.1) | 5327 (97.3) | 7821 (97.0) | 0.276 |
| Glucose-lowering drugs | 727 (5.5) | 209 (3.9) | 518 (6.6) | <0.001 |
BMI body mass index, DBP diastolic blood pressure, eGFR estimated glomerular filtration rate, SBP systolic blood pressure
aVariables are presented as mean (SD) or n (%)
Multiple analysis of baPWV and plaque presence
| baPWV, m/s | Plaque presence, | Nonadjusted | Adjusted | |||
|---|---|---|---|---|---|---|
| OR (95% CI) | OR (95% CI) | |||||
| Continuous | 13,554 | 5661 (41.8) | 1.12 (1.10, 1.13) | <0.001 | 1.05 (1.04, 1.07) | <0.001 |
| Quartile | ||||||
| Q1 (<14.81) | 3389 | 1044 (30.8) | Ref. | Ref. | ||
| Q2 (14.81 ≤ 16.73) | 3378 | 1240 (36.7) | 1.30 (1.18, 1.44) | <0.001 | 1.06 (0.95, 1.19) | 0.317 |
| Q3 (16.73 ≤ 19.06) | 3384 | 1547 (45.7) | 1.89 (1.71, 2.09) | <0.001 | 1.32 (1.17, 1.49) | <0.001 |
| Q4 (≥19.06) | 3403 | 1830 (53.8) | 2.61 (2.37, 2.89) | <0.001 | 1.49 (1.31, 1.70) | <0.001 |
| <0.001 | <0.001 | |||||
Adjusted for age, gender, BMI, alcohol consumption status, smoking status, SBP and DBP at baseline, TC, HDL-c; FPG, eGFR, homocysteine, folate, TG, glucose-lowering medication, antihypertensive medication, study center, and folic treatment group
BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, TC total cholesterol, HDL-c high-density lipoprotein cholesterol, FPG fasting plasma glucose, eGFR estimated glomerular filtration rate, TG triglyceride
Multinomial analysis of baPWV and carotid plaque number
| baPWV, m/s | One plaque | Two plaques | Three or more plaques | |||
|---|---|---|---|---|---|---|
| aOR (95% CI) | aOR (95% CI) | aOR (95% CI) | ||||
| Continuous | 1.04 (1.02, 1.06) | <0.001 | 1.04 (1.02, 1.06) | <0.001 | 1.09 (1.07, 1.12) | <0.001 |
| Quartiles | ||||||
| Q1 (<14.81) | Ref. | Ref. | Ref. | |||
| Q2 (14.81 ≤ 16.73) | 1.03 (0.89, 1.18) | 0.708 | 1.07 (0.88, 1.30) | 0.496 | 1.19 (0.96, 1.46) | 0.111 |
| Q3 (16.73 ≤ 19.06) | 1.15 (0.99, 1.33) | 0.072 | 1.47 (1.22, 1.79) | <0.001 | 1.67 (1.36, 2.06) | <0.001 |
| Q4 (≥19.06) | 1.27 (1.08, 1.50) | 0.005 | 1.45 (1.17, 1.79) | <0.001 | 2.20 (1.77, 2.74) | <0.001 |
| 0.002 | <0.001 | <0.001 | ||||
Adjusted for age, gender, BMI, alcohol consumption status, smoking status, SBP and DBP at baseline, TC, HDL-c; FPG, eGFR, homocysteine, folate, TG, glucose-lowering medication, antihypertensive medication, study center, and folic treatment group
aOR adjusted odds ratio, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, TC total cholesterol, HDL-c high-density lipoprotein cholesterol, FPG fasting plasma glucose, eGFR estimated glomerular filtration rate, TG triglyceride
Fig. 2Forest plots of the association between baPWV and plaque presence in various subgroups. Adjusted, if not stratified, for age, sex, body mass index (BMI), alcohol consumption status, smoking status, systolic, and diastolic blood pressure (SBP and DBP) at baseline, total cholesterol (TC), high-density lipoprotein cholesterol (HDL-c); fasting plasma glucose (FPG), estimated glomerular filtration rate (eGFR), homocysteine, folate, triglycerides (TG), glucose-lowering medication, antihypertensive medication, study center, folic treatment group